Largest Real-World Study of its Kind Highlights How RapidAI Aids in Identifying Challenging Aneurysms
New data presented at AANS 2025 reinforces RapidAI’s clinical leadership in neurovascular care and the growing role of AI in aneurysm detection. SAN MATEO, Calif. – April 28, 2025 – RapidAI, the gold standard in neurovascular AI-based clinical decision support and a leader in enterprise radiology solutions, today announced pivotal results from the most extensive real-world study to date on AI for aneurysm detection. Presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, the retrospective, single-center study analyzed 11,694 consecutive CTA scans1, demonstrating how RapidAI’s clinically validated platform, Rapid Aneurysm, can enhance diagnostic confidence and consistency, particularly in detecting nuanced or hard-to-visualize intracranial anomalies such as aneurysms when used in conjunction with standard clinical interpretation.
